Rubicon Research Private Limited

Other

Dipharma Sa

Psm Healthcare Limited

Towa Pharmaceutical Europe, S.l. Unipersonal

Amaterasu Lifesciences Llp

Breckenridge Pharmaceutical, Inc.

Maharukh Tehmasp Rustomjee

Anilkumar Surendrakumar Gandhi

Pratibha Sudhir Pilgaonkar

Pradnya M Bagde

Paras Jain

Atul A Kelkar

Varsha Barve

Rupali Kedar Suvarnapathaki

Vinderjit Sarjit Bhumra

Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one pharmaceutically acceptable organic acid, use of said compositions in the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and/or in the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and processes for the preparation of said compositions.

Oral pharmaceutical compositions of dabigatran etexilate

A gel composition comprising silicone crosspolymer and silicone oil wherein the composition when applied to the skin adheres to the skin with a work of adhesion of more than about 0.500 Newton&#xb7;sec when measured by TA.XT plus text analyzer using a mucoadhesive rig and forms a film with a coefficient of friction of less than 0.400 when measured by Automatic surface tester (method ASTM D 1894).

Anti chafing gel composition

The present invention relates to oral care compositions and to method of maintaining oral health. The oral care composition of the present invention comprises at least one carbon dioxide source, at least one acid source, at least one abrasive and one or more pharmaceutically acceptable excipients.

Oral care compositions

The present invention provides a composition exhibiting delayed transit through the gastrointestinal tract comprising one or more active agents, fenugreek fiber and at least one pharmaceutically acceptable excipient. The present invention further relates to gastroretentive dosage forms comprising fenugreek fibers.

Compositions exhibiting delayed transit through the gastrointestinal tract

An excipient from-seeds and a process for preparation thereof is disclosed. The excipient obtained from-seeds, comprising insoluble and soluble dietary fibers can be used in various pharmaceutical or cosmetic compositions and food, nutritional or dietary preparations.

[object Object]

The present invention relates to stable solid formulations of vitamin Dand to processes for preparation of the same. The present invention provides stabilized compositions comprising vitamin Dat least one lipophilic dispersant, one or more antioxidants, at least one adsorbent and one or more pharmaceutically acceptable excipients and further coated with a barrier coating.

Stabilized vitamin D formulations

The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.

Sustained release dosage form

The present invention relates to stable pharmaceutical compositions of tetrahydrobiopterin and processes for producing such compositions. Particularly the present invention relates to stable pharmaceutical compositions comprising tetrahydrobiopterin and at least one stabilizing agent.

Stable compositions of tetrahydrobiopterin

A solvent free process of obtaining an insoluble fiber rich fraction from-seeds is disclosed. The multifunctional fiber rich fraction (FRF) and highly purified FRF are useful as excipients for pharmaceutical dosage forms for various routes of administration. These excipients can be used as binder, disintegrant, filler, dispersing agent, coating agent, film forming agent, thickener and the like, for preparation of variety of dosage forms. FRF and highly purified FRF can also be used in a controlled release, targeted release and other specialized delivery systems, as well as in food and cosmetics formulation.

Disclosed herein is a dispersible tablet composition including a pharmacologically active ingredient and at least one excipient that reduces the sedimentation rate of the active ingredient and a process for preparing the same.

Dispersible tablet composition

The present invention describes a directly compressible composite excipient prepared by coating calcium silicate with a carbohydrate. The present invention further describes the incorporation of the composite excipient into a tablet formulation. The orally disintegrating tablets are of optimal mechanical strength and disintegrate within 60 seconds in the oral cavity.

Growing community of inventors

Mumbai, India

Maharukh Tehmasp Rustomjee